Effects of the oral TU Kyzatrex™ on ambulatory blood pressure in HG men

Buy Lab Tests Online

madman

Super Moderator
Abstract

Testosterone replacement therapies have been shown to increase blood pressure (BP) in hypogonadal men. We studied the effects of a new formulation of testosterone undecanoate (Kyzatrex™) on ambulatory blood pressure (ABP) and heart rate, in 155 men with hypogonadism (mean age, 50.5 years, 76.8% white, 36.1% on antihypertensive therapy).
The ABP, heart rate, and clinical assessments were obtained at baseline and following 120 and 180 days of therapy. Mean changes from baseline in 24-h ambulatory systolic BP of 1.7 mmHg (95% CI, 0.3, 3.1) at day 120 and 1.8 mmHg (95% CI, 0.3, 3.2) at day 180 were observed post-treatment. For those men on antihypertensive drug therapy, increases in mean 24-h systolic BP were greater than those not taking antihypertensive drugs (3.4 vs 0.7 mmHg at day 120, and 3.1 vs 1.0 mmHg at day 180, respectively). Changes from baseline in 24-h diastolic BP and heart rate at day 120 were smaller (<1 mmHg and <1 beat/min, respectively). There were no relationships observed between testosterone concentration or hemoglobin levels with ABP. Multivariable analyses showed that baseline ambulatory BP and antihypertensive therapy were significantly correlated with BP changes. These data demonstrate small increases in ambulatory BP following 120 days on this oral testosterone undecanoate with no further changes at 180 days. Changes in ambulatory BP were minimal in patients not taking antihypertensive therapy.




1  | INTRODUCTION

Testosterone replacement therapy for male hypogonadism or androgen deficiency has been administered by intramuscular and subcutaneous injections, transdermal gels and lotions, dermal patches, intranasal gels, and oral delivery.1 Testosterone itself has limited oral bioavailability. Long-chain fatty acid esterification of testosterone to create testosterone undecanoate allows for absorption via the intestinal lymphatic system and bypasses the first-pass metabolism in the liver.2 Testosterone is then liberated from testosterone undecanoate by endogenous non-specific esterases. Oral formulations of testosterone undecanoate have been developed to provide average serum testosterone levels in the eugonadal range (typically 300–1000 ng/dl) and avoid peak concentrations above 1500 ng/dl. During recent studies with both injectable and oral testosterone formulations, increases in both clinic and ambulatory blood pressure (BP) have been observed3,4 but the mechanism of these increases has not been elucidated nor has there been clarity regarding clinical predictors associated with BP increases. In the present BP safety study, we evaluated a new oral testosterone undecanoate therapy using ambulatory BP monitoring performed at baseline and following 120 and 180 days of daily therapy along with standard clinical and laboratory safety parameters.




5  |  CONCLUSIONS

In conclusion, this new oral formulation of testosterone undecanoate dosed between 100 mg once daily and 400 mg twice daily induced small increases in clinic and ambulatory BP. There were minimal increases in ambulatory heart rate that were not related to ambulatory BP changes. Study participants with a history of hypertension taking antihypertensive therapy and those with type 2 diabetes had larger increases in both ambulatory BP and heart rate following chronic oral testosterone undecanoate therapy than those without these 2 comorbidities. Hypogonadal men who were not receiving antihypertensive medication had negligible changes in ambulatory BP and heart rate.
 

Attachments

  • 2021JUNE11-ORALTU-BP-jch.14297.pdf
    352.5 KB · Views: 148
Defy Medical TRT clinic doctor
TABLE 1 Characteristics of the patient population at baseline (n = 155)
Screenshot (5033).png
 
FIGURE 1 Hourly ambulatory blood pressure (BP) results at baseline and 120 and 180 days after initiating oral testosterone undecanoate therapy. The upper panel depicts the ambulatory systolic BP; the lower panel shows the ambulatory diastolic BP
Screenshot (5027).png

Screenshot (5028).png
 
FIGURE 2 Cumulative distribution functions of percentage change from baseline to days 120 and 180 in ambulatory blood pressure. The upper panel depicts the ambulatory systolic BP; the lower panel shows the ambulatory diastolic BP
Screenshot (5029).png

Screenshot (5030).png
 
TABLE 3 Changes from baseline at Day 120 in 24-h blood pressure and heart rate in study participants with and without antihypertensive therapy and with and without diabetes mellitus following treatment with oral testosterone undecanoate
Screenshot (5031).png
 
TABLE 4 Change in 24-h average ambulatory SBP as a function of baseline SBP, dose, age, weight, diabetes, and baseline hypertensive treatment status by visit
Screenshot (5032).png
 
Buy Lab Tests Online
Defy Medical TRT clinic

Sponsors

bodybuilder test discounted labs
cheap enclomiphene
TRT in UK Balance my hormones
Discounted Labs
Testosterone Doctor Near Me
Testosterone books nelson vergel
Register on ExcelMale.com
Trimix HCG Offer Excelmale
BUY HCG CIALIS

Online statistics

Members online
3
Guests online
6
Total visitors
9

Latest posts

Top